Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwi

Launch marks first commercial availability of Joenja (leniolisib) for children aged 4 to 11 worldwid

Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects

Ratio Petroleum Energy has raised its recommended offer for Pharos Energy (LSE:PHAR) to 32.8183p per

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder righ

Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (“Pharm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Pharmin

Pharming Group shares fell 22% on July 30, 2026 after the Company reported a Q2 revenue decline and

A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026

NEW YORK--(BUSINESS WIRE)--A 22% single-session drop hit Pharming Group (PHAR) shares today after th

Leiden, the  Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHA

Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the

Pharming Group's legacy product RUCONEST posted a 10% year-over-year sales decline in Q2 2026 -- and

Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript

Pharming Group NASDAQ: PHAR reported second-quarter revenue of $90.2 million, down 3% from a year ea

Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session.

U.S. stock futures rise, Meta shares drop 9.4%, Teladoc Health and Rentokil Initial fall after mixed

Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.00

Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.02 per share which met the analyst consensu

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR - Get Free Report) have earned a consensus

Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administr

If approved, Joenja will be the first approved treatment in the U. S. for children with activated ph

Pharming Group announced that shareholders approved all proposals presented at its Annual General Me

Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline

Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript

Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $405.000 million-$425.000 million to $405.0

U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ:

Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other

For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 1

Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.07) per share which missed the analyst conse

Canaccord Genuity analyst Whitney Ijem initiates coverage on Pharming (NASDAQ:PHAR) with a Buy ra

If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union fo

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and

First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (AP

Oppenheimer analyst Jeff Jones reiterates Pharming (NASDAQ:PHAR) with a Outperform and lowers the

 For 2026, the Company anticipates:Total revenues between US$405 million and US$425 million (8% to 1

Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.07 per share which beat the analyst consens

Highlights advancing clinical-stage pipeline, including two major value-creating programs for primar

FDA issued a CRL to Pharming's Joenja child use filing, citing dosing concerns in lower-weight k